Skip to main content
Erschienen in: Annals of Surgical Oncology 11/2010

01.11.2010 | Head and Neck Oncology

Association of High Levels of Jagged-1 and Notch-1 Expression with Poor Prognosis in Head and Neck Cancer

verfasst von: Jen-Tsun Lin, MD, Mu-Kuan Chen, MD, PhD, Kun-Tu Yeh, MD, Cheng-Shyong Chang, MD, Tung-Hao Chang, MD, Chi-Yon Lin, MS, Yi-Chuan Wu, MS, Bi-Wen Su, MS, Kuan-Der Lee, MD, PhD, Pey-Jium Chang, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was to evaluate the prognostic value of the Jagged-1/Notch-1 expression in patients with head and neck carcinoma and to examine the possible role of the Jagged-1/Notch-1 signaling in tumorigenesis.

Methods

Immunohistochemical staining was performed on 59 formalin-fixed, paraffin-embedded head and neck carcinoma surgical specimens for Jagged-1 and Notch-1 expression. The head and neck cancer cell line, Fadu, with or without ectopic expression of the intracellular domain of Notch-1 (NICD) was also used for examining the tumorigenic capacity in vitro and in vivo.

Results

The study included 59 patients with a median age of 54 years (range, 35–73 years). Patients harboring tumors with both high-level Jagged-1 (J1Hi) and high-level Notch-1 (N1Hi) had a worse overall survival than the patients only with J1Hi or N1Hi as well as the patients with low-level Jagged-1 and Notch-1 (J1Lo/N1Lo) (P < 0.001). The 5-year survival rate and the median survival time were 5% and 10.9 months for J1Hi/N1Hi patients, while they were 35.04% and 47.7 months for non-J1Hi/NiHi patients. Ectopic expression of the active Notch-1 (NICD) in Fadu cells greatly enhanced cell migration and invasiveness in vitro and tumorigenic capacity in vivo.

Conclusions

High-level coexpression of Jagged-1 and Notch-1 is associated with poor overall survival in patients with head and neck cancer. Constitutive activation of the Notch signaling, which is possibly initiated by the direct interaction between Jagged-1 and Notch-1 in head and neck cancer, confers tumor cells with a more aggressive phenotype.
Literatur
1.
Zurück zum Zitat Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006;107:2223–33.CrossRefPubMed Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006;107:2223–33.CrossRefPubMed
2.
Zurück zum Zitat Koch U, Radtke F. Notch and cancer: a double-edged sword. Cell Mol Life Sci. 2007;64:2746–62.CrossRefPubMed Koch U, Radtke F. Notch and cancer: a double-edged sword. Cell Mol Life Sci. 2007;64:2746–62.CrossRefPubMed
3.
Zurück zum Zitat Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003;3:756–67.CrossRefPubMed Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003;3:756–67.CrossRefPubMed
4.
Zurück zum Zitat Egan SE, St-Pierre B, Leow CC. Notch receptors, partners and regulators: from conserve domains to powerful functions. Curr Top Microbiol Immunol. 1998;228:273–324.PubMed Egan SE, St-Pierre B, Leow CC. Notch receptors, partners and regulators: from conserve domains to powerful functions. Curr Top Microbiol Immunol. 1998;228:273–324.PubMed
5.
Zurück zum Zitat Dontu G, Al-Hajj M, Abdallah WM, et al. Stem cells in normal breast development and breast cancer. Cell Prolif. 2003;36(Suppl 1):59–72.CrossRefPubMed Dontu G, Al-Hajj M, Abdallah WM, et al. Stem cells in normal breast development and breast cancer. Cell Prolif. 2003;36(Suppl 1):59–72.CrossRefPubMed
6.
Zurück zum Zitat Dontu G, Jackson KW, McNicholas E, et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6:R605–15.CrossRefPubMed Dontu G, Jackson KW, McNicholas E, et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6:R605–15.CrossRefPubMed
8.
Zurück zum Zitat Miele L, Miao H, Nickoloff BH. Notch signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets. 2006;6:313–23.CrossRefPubMed Miele L, Miao H, Nickoloff BH. Notch signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets. 2006;6:313–23.CrossRefPubMed
9.
Zurück zum Zitat Wang Z, Banerjee S, Li Y, et al. Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-κB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006;66:2778–84.CrossRefPubMed Wang Z, Banerjee S, Li Y, et al. Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-κB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006;66:2778–84.CrossRefPubMed
10.
Zurück zum Zitat Wang Z, Zhang Y, Li Y, et al. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006;5:483–93.CrossRefPubMed Wang Z, Zhang Y, Li Y, et al. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006;5:483–93.CrossRefPubMed
11.
Zurück zum Zitat Dickson BC, Mulligan AM, Zhang H, et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol. 2007;20:685–93.CrossRefPubMed Dickson BC, Mulligan AM, Zhang H, et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol. 2007;20:685–93.CrossRefPubMed
12.
Zurück zum Zitat Santagata S, Demichelis F, Riva A, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004;64:6854–7.CrossRefPubMed Santagata S, Demichelis F, Riva A, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004;64:6854–7.CrossRefPubMed
13.
Zurück zum Zitat Mungamuri K, Yang X, Thor AD, et al. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006;66:4715–24.CrossRefPubMed Mungamuri K, Yang X, Thor AD, et al. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006;66:4715–24.CrossRefPubMed
14.
Zurück zum Zitat Nakamura T, Tsuchiya K, Watanabe M. Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J Gastroenterol. 2007;27:705–10.CrossRef Nakamura T, Tsuchiya K, Watanabe M. Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J Gastroenterol. 2007;27:705–10.CrossRef
15.
Zurück zum Zitat Osipo C, Golde TE, Osborne BA, et al. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest. 2008;88:11–7.CrossRefPubMed Osipo C, Golde TE, Osborne BA, et al. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest. 2008;88:11–7.CrossRefPubMed
16.
Zurück zum Zitat Timmerman LA, Grego-Bessa J, Raya A, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004;18:99–115.CrossRefPubMed Timmerman LA, Grego-Bessa J, Raya A, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004;18:99–115.CrossRefPubMed
17.
Zurück zum Zitat Zavadil J, Cermak L, Soto-Nieves N, et al. Integration of TGF-β/Smad and Jagged1/Notch signaling in epithelial-to-mesenchymal transition. EMBO J. 2004;23:1155–65.CrossRefPubMed Zavadil J, Cermak L, Soto-Nieves N, et al. Integration of TGF-β/Smad and Jagged1/Notch signaling in epithelial-to-mesenchymal transition. EMBO J. 2004;23:1155–65.CrossRefPubMed
18.
Zurück zum Zitat Sahlgren C, Gustafsson MV, Jin S, et al. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA. 2008;105:6392–7.CrossRefPubMed Sahlgren C, Gustafsson MV, Jin S, et al. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA. 2008;105:6392–7.CrossRefPubMed
19.
20.
Zurück zum Zitat Dievart A, Beaulieu N, Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene. 1999;18:5973–81.CrossRefPubMed Dievart A, Beaulieu N, Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene. 1999;18:5973–81.CrossRefPubMed
21.
Zurück zum Zitat Kiaris H, Politi K, Grimm LM, et al. Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. Am J Pathol. 2004;165:695–705.PubMed Kiaris H, Politi K, Grimm LM, et al. Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. Am J Pathol. 2004;165:695–705.PubMed
22.
Zurück zum Zitat Tohda S, Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk Lymphoma. 2001;42:467–72.CrossRefPubMed Tohda S, Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk Lymphoma. 2001;42:467–72.CrossRefPubMed
23.
Zurück zum Zitat Ascano JM, Beverly LJ, Capobianco AJ. The C terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. J Biol Chem. 2003;278:8771–9.CrossRefPubMed Ascano JM, Beverly LJ, Capobianco AJ. The C terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. J Biol Chem. 2003;278:8771–9.CrossRefPubMed
24.
Zurück zum Zitat Mani SA, Guo WJ, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.CrossRefPubMed Mani SA, Guo WJ, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.CrossRefPubMed
25.
Zurück zum Zitat Zeng QH, Li SG, Chepeha DB, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell. 2005;8:13–23.CrossRefPubMed Zeng QH, Li SG, Chepeha DB, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell. 2005;8:13–23.CrossRefPubMed
Metadaten
Titel
Association of High Levels of Jagged-1 and Notch-1 Expression with Poor Prognosis in Head and Neck Cancer
verfasst von
Jen-Tsun Lin, MD
Mu-Kuan Chen, MD, PhD
Kun-Tu Yeh, MD
Cheng-Shyong Chang, MD
Tung-Hao Chang, MD
Chi-Yon Lin, MS
Yi-Chuan Wu, MS
Bi-Wen Su, MS
Kuan-Der Lee, MD, PhD
Pey-Jium Chang, PhD
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1118-9

Weitere Artikel der Ausgabe 11/2010

Annals of Surgical Oncology 11/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.